VentureMed Group Raises $28M in Series C Funding

Why It Matters

The infusion enables VentureMed to scale clinical trials and launch new devices, addressing a growing demand for minimally invasive vascular solutions and potentially reshaping the PAD and AVF/AVG treatment landscape.

Key Takeaways

• $28M Series C led by S3 Ventures.
• Funds target clinical program expansion.
• Focus on adjacent vascular applications.
• FLEX system cleared FDA and CE.
• Treats PAD and AVF/AVG with vessel prep tech.

Pulse Analysis

VentureMed Group’s $28 million Series C round underscores the accelerating flow of capital into vascular‑focused medical‑device firms. Led by S3 Ventures and backed by existing backer Endeavour Vision, the financing arrives at a pivotal growth stage where companies shift from prototype validation to large‑scale clinical trials and commercial rollout. In 2025, U.S. venture investment in health‑tech reached a record $12 billion, with a noticeable tilt toward solutions that address chronic circulatory disorders. VentureMed’s infusion of cash therefore aligns with broader investor confidence that innovative vessel‑preparation tools can capture significant market share.

The company’s flagship FLEX Vessel Prep System leverages proprietary Kinetic Endovascular Micro‑incision Creation (KEMIC) technology to produce controlled, longitudinal micro‑incisions that improve luminal gain and reduce trauma during access. FDA 510(k) clearance and CE Mark approval give the device a dual‑market advantage, enabling rapid entry into both North American and European vascular suites. By standardizing vessel preparation for peripheral arterial disease and arteriovenous fistula creation, FLEX addresses a long‑standing procedural bottleneck, potentially lowering complication rates and shortening procedure times—metrics that resonate with hospitals seeking cost‑effective, outcome‑driven solutions.

With the infusion of $28 million, VentureMed is positioned to broaden its pipeline into adjacent vascular territories such as coronary and neuro‑intervention, where precise vessel preparation is increasingly demanded. The capital will also fund expanded multicenter trials, data generation for reimbursement, and scaling of manufacturing capabilities. Competitors like Medtronic and Boston Scientific have begun integrating similar preparation tools, but VentureMed’s early‑stage KEMIC platform offers a differentiated, less invasive approach. If clinical outcomes meet expectations, the company could capture a sizable slice of the projected $12 billion global vascular access market by 2030.